Under the deal, Eli Lilly will pay roughly $880 million to acquire Prevail, and will pay another $160 million if one of Prevail’s drugs is FDA-approved by the end of 2024.
Eli Lilly said the acquisition will help it create a gene therapy program, which will be anchored by Prevail’s portfolio of clinical stage and preclinical neurodegenerative disease drugs. The drugs it has in development are designed to treat diseases including Parkinson’s and Alzheimer’s.
“Gene therapy is a promising approach with the potential to deliver transformative treatments for patients with neurodegenerative diseases such as Parkinson’s, Gaucher and dementia,” said Mark Mintun, MD, vice president of pain and neurodegeneration research at Eli Lilly.
The deal is expected to close in the first quarter of 2021.
Read the full news release here.
More articles on pharmacy:
UK approves AstraZeneca’s COVID-19 vaccine
More than 2 million people vaccinated, up to 15.7M doses expected to ship by end of year
Wisconsin hospital discards hundreds of COVID-19 vaccines after improper storage
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
